immunate
immuno produtos biolÓgicos e quÍmicos ltda - sangue, derivados e substitutos exceto imunoprotecao
immunate s/d
baxter hospitalar ltda - fracoes do sangue ou plasma exceto gamaglobulina
immunine
immuno produtos biolÓgicos e quÍmicos ltda - sangue, derivados e substitutos exceto imunoprotecao
immunine 600 u.i./5 ml pó e solvente para solução injetável ou para perfusão
baxalta innovations gmbh - factor ix da coagulação humana - pó e solvente para solução injetável ou para perfusão - 600 u.i./5 ml - factor ix da coagulação humana 600 u.i. - coagulation factor ix - derivado do sangue e plasma humano - duração do tratamento: curta ou média duração
immunate 500 ui/5 ml + 375 ui/5 ml pó e solvente para solução injetável
baxalta innovations gmbh - factor viii da coagulação humana + factor de von willebrand humano - pó e solvente para solução injetável - 500 ui/5 ml + 375 ui/5 ml - factor viii da coagulação humana 500 u.i. ; factor de von willebrand humano 250 u.i. - von willebrand factor and coagulation factor viii in combination - derivado do sangue e plasma humano - duração do tratamento: curta ou média duração
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agentes antineoplásicos - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. veja as seções 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
claritromicina bluepharma lp 500 mg comprimido de libertação prolongada
bluepharma genéricos - comércio de medicamentos s.a. - claritromicina - comprimido de libertação prolongada - 500 mg - claritromicina, citrato 638.8 mg - clarithromycin - genérico - duração do tratamento: curta ou média duração
claritromicina bluepharma lp 500 mg comprimido de libertação prolongada
bluepharma genéricos - comércio de medicamentos s.a. - claritromicina - comprimido de libertação prolongada - 500 mg - claritromicina, citrato 638.8 mg - clarithromycin - genérico - duração do tratamento: curta ou média duração